Abstract
Bone health related skeletal disorders are commonly diagnosed by X-ray imaging, but the radiation limits its use. Light excitation and optical imaging through the near-infrared-II window (NIR-II, 1000-1700 nm) can penetrate deep tissues without radiation risk, but the targeting of contrast agent is non-specific. Here, we report that lanthanide-doped nanocrystals can be passively transported by endothelial cells and macrophages from the blood vessels into bone marrow microenvironment. We found that this passive targeting scheme can be effective for longer than two months. We therefore developed an intravital 3D and high-resolution planar imaging instrumentation for bone disease diagnosis. We demonstrated the regular monitoring of 1 mm bone defects for over 10 days, with resolution similar to X-ray imaging result, but more flexible use in prognosis. Moreover, the passive targeting can be used to reveal the early onset inflammation at the joints as the synovitis in the early stage of rheumatoid arthritis. Furthermore, the proposed method is comparable to μCT in recognizing symptoms of osteoarthritis, including the mild hyperostosis in femur which is ~100 μm thicker than normal, and the growth of millimeter-scale osteophyte in the knee joint, which further proves the power and universality of our approach in diagnosis of bone diseases.
Introduction
Diagnosing bone disorders such as fractures, osteoporosis, and arthritis typically relies on X-ray or Computed Tomography (CT). While effective, these methods expose patients to ionizing radiation, a known carcinogen. Cumulative exposure is a significant concern for pediatric patients and individuals requiring long-term monitoring. Optical imaging offers a safer, non-ionizing alternative; however, it has historically faced two major hurdles: limited tissue penetration due to light scattering and the difficulty of targeting contrast agents to bone. Most nanoparticles are rapidly cleared by the liver and spleen, with less than 1% typically reaching the skeletal system.
This research presents a significant leap in skeletal imaging by utilizing specialized lanthanide-doped nanoparticles and the near-infrared-IIb (NIR-IIb) window (1500–1700 nm). By leveraging a unique biological transport mechanism, the researchers have enabled high-resolution, 3D optical monitoring of bone diseases with a clarity previously reserved for X-rays.
Methods and Materials
The authors addressed the challenges of depth and targeting through a combination of advanced materials science and a "Trojan Horse" biological strategy.
The NIR-IIb Probe
The team synthesized core-shell nanocrystals (NaYbF4: Er3+, Ce3+ @NaYF4), referred to as ErNCs, which emit light at approximately 1550 nm. This wavelength falls within the NIR-IIb window, where biological tissues are most transparent. This allows for deep penetration and minimal background autofluorescence, which often plagues visible-light imaging.
Surface Modification and Targeting
The particles were coated with polyethylene glycol (PEG) to extend their circulation time and evade initial immune clearance. Rather than attempting to chemically bond the particles to bone minerals (like hydroxyapatite), the researchers discovered a "passive" targeting mechanism: the body’s own macrophages and endothelial cells actively transport these nanoparticles from the blood vessels into the bone marrow microenvironment.
3D Instrumentation
To translate these signals into diagnostic data, the team developed a custom intravital imaging setup. This system uses multi-angle rotation to reconstruct 3D images of bones, functioning similarly to a CT scan but utilizing light instead of ionizing radiation.
Key Insights
Cellular Transport Mechanism
A pivotal finding of this study was the confirmation of the accumulation mechanism. While previous assumptions suggested nanoparticles might bind to bone minerals, this study demonstrated that the signal vanishes if the bone marrow is flushed. This confirms that the particles are housed within the marrow, carried there by active cellular transport rather than simple mineral binding.
Long-term Monitoring
The passive targeting scheme remains effective for over 70 days. This unprecedented longevity allows for longitudinal studies of healing and disease progression without the need for repeated injections of contrast agents, making it ideal for monitoring chronic conditions or recovery from surgery.
Resolution Breakthrough
By operating at the 1550 nm wavelength, the system achieved a spatial resolution of ~0.64 mm. This resolution is sufficient to distinguish fine structures such as the growth plate and subchondral bone, which are typically blurred in standard optical imaging.
Results
The efficacy of the NIR-IIb system was validated across several animal models, including bone defects, collagen-induced arthritis (CIA), and anterior cruciate ligament transection (ACLT) for osteoarthritis.
- Bone Defect Detection: The system accurately resolved 1.2 mm bone defects in mouse tibias, matching X-ray measurements almost perfectly and allowing for the monitoring of the healing process over 10 days.
- Early Arthritis Diagnosis: The method successfully detected synovitis (joint inflammation) in the early stages of rheumatoid arthritis. It identified specific inflamed toe joints that appeared normal under standard bright-field inspection, suggesting a higher sensitivity for early intervention.
- Osteoarthritis Symptoms: The imaging identified osteophytes (bone spurs) and hyperostosis (abnormal bone thickening). Specifically, it detected femur thickening of ~200 μm, a finding confirmed by clinical-standard μCT.
- Biocompatibility: Toxicity assays and H&E staining showed no damage to organs or cellular structures even 70 days post-injection, with the particles eventually being excreted naturally.
Discussion and Future Work
While this method represents a breakthrough in small-animal imaging, several challenges remain for human clinical translation. Human bones are significantly thicker and deeper than those of mice, necessitating further exploration into longer wavelengths or more sensitive detectors. Additionally, while passive targeting via macrophages is effective for general imaging, future iterations may incorporate "active" ligands to distinguish between specific bone cell types, such as osteoblasts and osteoclasts. Finally, the long-term residence of nanoparticles in the bone marrow (over 2 months) will require extensive safety profiling to meet regulatory standards for human use.
Summary updated